{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-177016","form_type":"8-K","ticker":null,"cik":"0001305253","company_name":"Eiger BioPharmaceuticals, Inc.","filed_at":"2024-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.519595+00:00","generated_at":"2026-05-31T21:59:34.701313+00:00","sec_items":["2.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Eiger sells Avexitide to Amylyx for $35.1M in bankruptcy sale closed July 9","bullets":["Sold Avexitide asset to Amylyx Pharmaceuticals for $35.1M plus assumed cure costs and liabilities.","Bankruptcy Court approved sale on June 26, 2024; transaction closed July 9, 2024.","Amylyx will handle development, manufacturing, and commercialization of Avexitide.","Eiger's common stock (EIGRQ) trades on OTC Pink; company cautions of potential total loss for securityholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-177016","json":"https://secwatch.observer/filing/0001193125-24-177016.json","markdown":"https://secwatch.observer/filing/0001193125-24-177016.md","text":"https://secwatch.observer/filing/0001193125-24-177016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524177016/0001193125-24-177016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524177016/d861769d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:59:34.701313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c94771723f1456dbc70609024ddcfe18b9ca0e0","claim":"Eiger BioPharmaceuticals, Inc. completed a disposition involving Amylyx Pharmaceuticals, Inc. for $35.1 million (closed 2024-07-09).","evidence_excerpt":"the Company’s rights, title and interests in, to and under those assets and interests used by the Company in the development, manufacture and commercialization of Avexitide for $35.1 million, plus the aggregate amount of determined cure costs and assumed liabilities. At a hearing held on June 26, 2024, the Bankruptcy Court approved the sale of the Company’s Avexitide","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524177016/0001193125-24-177016-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Amylyx Pharmaceuticals, Inc."},{"label":"Consideration","value":"$35.1 million"},{"label":"Closing","value":"2024-07-09"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}